(Sharecast News) - Eli Lilly said on Monday that it has agreed to buy Boston-based Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7bn in cash.
Under the terms of the agreement, Lilly will make an upfront payment of $3.25bn, and subsequent payments upon achievement...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE